Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 28 Triple Negative Breast Neoplasms 12 Prostatic Neoplasms 12 Ovarian Neoplasms 10 Neoplasms 10 Neoplasm Metastasis 9 Leukemia, Myeloid, Acute 5 Fallopian Tube Neoplasms 5 Small Cell Lung Carcinoma 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Solid Tumors 4 Pancreatic Neoplasms 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma, Ewing 2 Recurrence 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Carcinoma, Renal Cell 2 Carcinoma, Ovarian Epithelial 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Thrombocythemia, Essential 1 Solid Tumor 1 Sarcoma 1 Rhabdomyosarcoma 1

Interventions

Carboplatin 301 Cisplatin 220 Radiotherapy 188 Paclitaxel 179 Pemetrexed 168 Docetaxel 157 Gemcitabine 140 pembrolizumab 132 Erlotinib Hydrochloride 100 Magnetic Resonance Spectroscopy 92 Etoposide 89 Bevacizumab 79 Specimen Handling 75 durvalumab 68 Nivolumab 66 Radiosurgery 64 Drug Therapy 55 Blood Specimen Collection 51 Vinorelbine 50 osimertinib 48 Gefitinib 42 Surveys and Questionnaires 40 Biopsy 40 atezolizumab 37 Radiation 37 Irinotecan 37 Topotecan 35 Cyclophosphamide 35 Standard of Care 34 Surgical Procedures, Operative 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04170946 2026-03-05

Talazoparib

University Health Network, Toronto

Phase 1 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡